Researchers believe that identifying mutations in tumor genes may someday help guide treatment decisions. Because the amount of tumor biopsy tissue is limited, it is important to gain as much information as possible about a uveal melanoma tumor from a single biopsy. To provide additional genetic information from your biopsy, Castle Biosciences offers an optional gene sequencing panel that can find mutations in seven important genes in your uveal melanoma tumor. The gene sequencing panel, DecisionDx-UMSeq is an additional test that can be run on the same sample as your DecisionDx®-UM GEP test.
The results of the DecisionDx-UMSeq panel, along with those from the DecisionDx-UM and DecisionDx-PRAME tests, will provide your physician with a comprehensive genomic profile of your UM tumor from a single biopsy. This genomic information can be used to help guide your care, and may also become useful in the future as UM scientific research and therapeutics evolve. In the majority of cases, your ophthalmologist will only collect a single biopsy sample. We offer
DecisionDx-PRAME and DecisionDx-UMSeq because your biopsy sample is precious and we believe that providing as much genomic information as possible is the right and ethical decision.
It is important to remember that information from the gene sequencing panel is NOT a substitute for the DecisionDx-UM GEP test. The DecisionDx-UM GEP test is the only uveal melanoma prognostic method that has been prospectively validated in multiple studies, providing the most robust prognostic information.
DecisionDx-UMSeq can be ordered for any patient who is having DecisionDx-UM GEP testing. No additional biopsy is required. The DecisionDx-UMSeq gene sequencing panel will be submitted to your insurance company for payment.